

Intramuscular or combined intramuscular/intra-arterial administration of bone marrow mononuclear cells in patients with advanced limb ischaemia

Submission date 16/07/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 16/07/2007	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 31/12/2020	Condition category Circulatory System	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Jan H. Lindeman

Contact details

Leiden University Medical Centre
Department of Vascular Surgery
P.O. Box 9600
Leiden
Netherlands
2300 RC

-
Lindeman@lumc.nl

Additional identifiers

Protocol serial number

N/A

Study information

Scientific Title

Intramuscular or combined intramuscular/intra-arterial administration of bone marrow mononuclear cells in patients with advanced limb ischaemia

Study objectives

The primary aim of our study was to test the feasibility and safety of exclusively intramuscular, and combined intramuscular/intra-arterial delivery of Bone marrow Mononuclear Cells (BMC) in patients with advanced limb ischaemia without conventional options for surgical or endovascular treatment.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Medical Ethical Committee of the Leiden University Medical Centre on December 12, 2003 (ref: P03.149).

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Bone marrow mononuclear cells in patients with advanced limb ischaemia

Interventions

Hospital admittance was planned in a short-stay setting (24 - 48 hours). The harvest procedure was performed according to standard protocols for bone marrow donation for allogeneic transplantation. 750 millilitre bone marrow was collected from the posterior iliac crest under epidural or general anaesthesia. The suspension was filtered and subsequently concentrated in a final volume of 40 mL. Upon concentration of the BMC-fraction, the erythrocyte fraction was collected separately and re-infused to the patient.

The mononuclear cells were implanted approximately 4 hours after bone marrow aspiration. The method of administration was randomly assigned to the patients using a random number table:

1. By local injection into the gastrocnemius muscle
2. By combined Intramuscular (IM) and Intra-Arterial (IA) delivery

The investigators were not blinded for the assignment. In case of total IM delivery, we implanted 1 ml using a 26-gauge needle on 40 sites, 1.5 cm deep, using the full surface of the gastrocnemius muscle. In patients assigned to the combined treatment arm, the volume of each IM injection was 0.5 ml. The remaining 20 ml was slowly infused after selective catheterisation of the superficial femoral artery (or profunda femoral artery in case of occlusion of the Superficial Femoral Artery [SFA]), performed according to the standard procedures within the Department of Radiology.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

1. Wound healing/limb salvage (Fontaine 3/4), measured at 6 months
2. Pain-free walking distance (Fontaine 2), measured at 6 months

Key secondary outcome(s)

1. Ankle/brachial index, measured at 3, 6 and 12 months
2. Pain scores (Brief Pain Inventory), measured at 3, 6 and 12 months
3. Quality of Life (RAND-36), measured at 3, 6 and 12 months
4. Artery scores (angiogram), measured at 6 months
5. Limb salvage/wound healing and pain free walking distance at 3 and 12 months

Completion date

01/01/2006

Eligibility

Key inclusion criteria

1. Disabling claudication (Fontaines stages IIb/III or Rutherfords categories 3/4) or critical limb ischaemia (Fontaines stages IV or Rutherfords categories 5/6) despite greater than six months optimal medical therapy
2. Ineligibility for angioplasty or bypass procedures
3. Male or female, greater than 18 years old
4. Life expectancy greater than one year
5. Written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

16

Key exclusion criteria

1. Candidates for angioplasty or bypass procedures
2. Inability to undergo bone marrow harvesting
3. Life threatening co-morbidity
4. International Normalised Ratio (INR) greater than 2
5. History of malignant disease in five years prior to treatment
6. Inability to undergo arterial catheterisation
7. Inability to follow the protocol and to comply with the follow up requirements
8. Any other conditions that, in the opinion of the investigators, could interfere with the therapy or could pose a significant threat to the subject if the investigational therapy was to be initiated

Date of first enrolment

01/01/2004

Date of final enrolment

01/01/2006

Locations

Countries of recruitment

Netherlands

Study participating centre

Leiden University Medical Centre

Leiden

Netherlands

2300 RC

Sponsor information

Organisation

Leiden University Medical Centre (LUMC) (The Netherlands)

ROR

<https://ror.org/027bh9e22>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2010	31/12/2020	Yes	No